|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Based on MBD-Seq, we characterized the global methylation profile of high CpG-rich regions in different CLL prognostic subgroups based on IGHV mutational status.
|
27777635 |
2016 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Based on the expression of 3521 identified proteins, principal component analysis separated CLL samples into two groups corresponding to immunoglobulin heavy chain variable region mutational status.
|
25645933 |
2015 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Biological markers (CD38, ZAP-70, and IGHV mutational status) and gene expression profiles (GEP) of leukemic cells from CLL patients included in a prospective multicenter observational study (O-CLL1-GISL protocol, clinicaltrial.gov ID:NCT00917549) were used to assess the value and reproducibility of this score.
|
24711230 |
2014 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
|
16938520 |
2006 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Bootstrap univariate Cox regression analysis confirmed that HIF1A mRNA overexpression is a significant unfavorable prognosticator in CLL (hazard ratio=3.75, bias-corrected and accelerated 95% confidence interval=1.43-24.36, bootstrap p<0.001), independent of other established prognostic factors, including CD38 expression, the mutational status of the immunoglobulin heavy chain variable region (IGHV), and the clinical stage (Binet or Rai stage) or risk group (p<0.001 in all cases).
|
28038356 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Both CLL and MCL include 2 major molecular subtypes that seem to derive from antigen-experienced CD5<sup>+</sup> B cells that retain a naive or memory-like epigenetic signature and carry a variable load of immunoglobulin heavy-chain variable region somatic mutations from truly unmutated to highly mutated, respectively.
|
29666114 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
|
26559905 |
2016 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
CD49d, the alpha-chain of the integrin heterodimer α4β1, was identified among the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia (CLL), along with IGHV mutational status and deletion of the 17p chromosome involving TP53.
|
27109509 |
2016 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Cell surface expression of CD150 and CD180 receptors in chronic lymphocytic leukemia (CLL) associates with mutational IGHV status and favourable prognosis.
|
28982149 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL).
|
31447270 |
2019 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Chromosomal aberrations, IGHV and TP53 mutation status are well-established and essential to discriminate between a more indolent course of disease and a high-risk CLL, which requires an alternative treatment regimen.
|
26890126 |
2016 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Chromosomal abnormalities, immunoglobulin heavy chain variable-region (IGHV) gene mutation status, and zeta-associated protein 70 (ZAP-70) expression levels have independent prognostic relevance in chronic lymphocytic leukemia (CLL); however, their concordance is variable.
|
19717645 |
2009 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis.
|
20110453 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.
|
22899580 |
2013 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance.
|
23893575 |
2013 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
CTRAs were assigned to two categories (i) CTRAs present in the context of KC, often with involvement of chromosome 17p aberrations, occurring mostly in CLL with unmutated IGHV genes; in such cases, we found that KC rather than the presence of CTRAs per se negatively impacts on survival; (ii) CTRAs in cases without KC, having limited if any impact on survival.
|
24166834 |
2014 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Currently, a cut-off of 2% deviation or 98% sequence identity to germline in IGHV sequence is routinely used to dichotomize CLL patients into mutated and unmutated groups.
|
29164608 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients.
|
31054420 |
2019 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia.
|
2503826 |
1989 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Evidence for immunoglobulin heavy chain variable region gene replacement in a patient with B cell chronic lymphocytic leukemia.
|
8751479 |
1996 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Expression of S1P2, which controls B-cell homeostasis, is also impaired in CLL B cells but independently of the IGHV mutational status.
|
23033271 |
2012 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Finally, in certain instances, as in the case of chronic lymphocytic leukemia (CLL), the clonotypic IG sequence and, more specifically, the load of somatic hypermutations within the rearranged IG heavy variable (IGHV) gene, holds prognostic and potentially predictive value.
|
30350197 |
2019 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Finally, LPL protein expression correlated significantly with mRNA expression and was higher in IGHV unmutated versus mutated CLL (p=0.018), although the majority of synthesized protein was catalytically inactive indicating a non-catalytical function in CLL.
|
19709746 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Fluorescent-labeled DNA probes were used to study 52 chronic lymphocytic leukemia (B-CLL) patients for (1) disease progression, (2) angiogenesis genes, (3) T-cell leukemia 1 gene (TCL1), (4) immunoglobulin heavy chain variable region (IGHv) and (5) chromosome 6q.
|
15661260 |
2005 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
For patients with mutated IGHV genes, reduced kappa/lambda ratios were adversely prognostic and associated with the poor prognostic IGHV3-21, IGHV3-48 and IGHV3-53 subgroups, suggesting an abnormal sFLC ratio may reflect biological subgroups within CLL.
|
19016722 |
2009 |